Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more
Kangstem Biotech Co. Ltd (217730) - Total Assets
Latest total assets as of September 2025: ₩76.42 Billion KRW
Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) holds total assets worth ₩76.42 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kangstem Biotech Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Kangstem Biotech Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kangstem Biotech Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Kangstem Biotech Co. Ltd's total assets of ₩76.42 Billion consist of 51.0% current assets and 49.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩2.77 Billion | 4.9% |
| Accounts Receivable | ₩2.51 Billion | 4.5% |
| Inventory | ₩858.30 Million | 1.5% |
| Property, Plant & Equipment | ₩19.30 Billion | 34.5% |
| Intangible Assets | ₩975.71 Million | 1.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Kangstem Biotech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kangstem Biotech Co. Ltd's current assets represent 51.0% of total assets in 2024, a decrease from 75.6% in 2015.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2024, down from 20.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 34.5% of total assets.
Kangstem Biotech Co. Ltd Competitors by Total Assets
Key competitors of Kangstem Biotech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Kangstem Biotech Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kangstem Biotech Co. Ltd generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kangstem Biotech Co. Ltd is currently not profitable relative to its asset base.
Kangstem Biotech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.30 | 2.97 | 3.67 |
| Quick Ratio | 7.18 | 2.90 | 3.64 |
| Cash Ratio | 0.00 | 0.11 | 0.00 |
| Working Capital | ₩43.24 Billion | ₩ 23.80 Billion | ₩ 32.54 Billion |
Kangstem Biotech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Kangstem Biotech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.03 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -31.1% |
| Total Assets | ₩55.99 Billion |
| Market Capitalization | $74.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kangstem Biotech Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kangstem Biotech Co. Ltd's assets decreased by 31.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kangstem Biotech Co. Ltd (2015–2024)
The table below shows the annual total assets of Kangstem Biotech Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩55.99 Billion | -31.10% |
| 2023-12-31 | ₩81.25 Billion | +0.82% |
| 2022-12-31 | ₩80.59 Billion | -21.87% |
| 2021-12-31 | ₩103.15 Billion | +25.02% |
| 2020-12-31 | ₩82.51 Billion | -27.40% |
| 2019-12-31 | ₩113.64 Billion | +55.26% |
| 2018-12-31 | ₩73.19 Billion | +59.42% |
| 2017-12-31 | ₩45.91 Billion | -3.22% |
| 2016-12-31 | ₩47.44 Billion | +89.90% |
| 2015-12-31 | ₩24.98 Billion | -- |